Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Pierre Fabre Medicament Production
WARNING LETTER
•Pierre Fabre Medicament Production•September 8, 2009

Pierre Fabre Medicament Production – FDA Warning Letter, Sep 8, 2009

Record Details

This FDA Warning Letter, dated March 26, 2010, was issued to Pierre Fabre Medicament Production - Aquitaine Pharm International 2 following an inspection from September 1-8, 2009. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for Finished Pharmaceuticals (21 CFR Parts 210 and 211), rendering their drug products adulterated. The firm's September 29, 2009, response was deemed insufficient.

Key violations include: 1. **Failure to thoroughly investigate unexplained discrepancies (21 CFR § 211.192):** * Aloxi (Palonosetron HCl) injection batches failed yield limits, with no identified root cause for high particle content or impact assessment. * Uninvestigated out-of-limit (OOL) in-process fill weight results for validation batches, with inconsistent fill weight specifications. * Inadequate investigation of OOL non-viable particle counts in critical areas during validation, with a new procedure implemented post-manufacturing. * Failure to investigate critical defects (particles) found during self-check visual inspections after multiple automated and manual inspections, indicating inadequate control. 2. **Failure to establish and follow written procedures for in-process controls (21 CFR § 211.110(a)):** High vial

Company
Pierre Fabre Medicament Production
Inspection date
September 8, 2009
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Teddi Lopez
  • Richard L. Friedman (Director)
  • Rafael E. Arroyo (Senior Policy Advisor)
View Company Profile

ID · fe727439-3788-4399-ba2e-ef3243584753

Violation Codes9
21 CFR 21021 CFR 21121 CFR 211.19221 CFR 211.110(a)21 CFR 211.100(b)21 U.S.C. 381(a)(3)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Pierre Fabre Medicament Production
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.